GlassScriptPhysician profile
Kellie Kozak
NPI 1255716825
$1,923.67
in general payments reported to CMS, 2019-2025
21 companies · $730 in 2025
The $730 reported for 2025 was more than what 78% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $366 · 2022: $134 · 2023: $504 · 2024: $189 · 2025: $730.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,305 · Education: $118.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,305.35 |
| Education | $117.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $453.59 | 2021-2025 | Breztri, Bevespi Aerosphere, Fasenra |
| Genzyme Corporation | $301.39 | 2021-2025 | |
| Glaxosmithkline, LLC. | $212.55 | 2021-2025 | Nucala, Trelegy Ellipta |
| Regeneron Healthcare Solutions, INC. | $175.38 | 2021-2024 | Dupixent |
| Sanofi-Aventis U.S. LLC | $117.98 | 2023-2025 | |
| Ars Pharmaceuticals Operations, INC. | $92.04 | 2025 | Neffy |
| Amgen INC. | $91.26 | 2023-2025 | Tezspire |
| Genentech USA, INC. | $64.73 | 2025 | Xolair |
| Takeda Pharmaceuticals U.S.A., INC. | $60.51 | 2023 | Hyqvia, Takhzyro |
| Grifols USA, LLC | $60.10 | 2021-2024 | Xembify |
| Alk-Abello, INC | $50.00 | 2023-2025 | Odactra, Grastek, Ragwitek |
| Csl Behring | $49.48 | 2021-2024 | Privigen, Hizentra |
| Optinose US, INC. | $40.64 | 2021-2025 | |
| Octapharma USA, INC. | $27.60 | 2024 | Octagam Immune Globulin (Human) |
| Pfizer INC. | $25.78 | 2023 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharming Healthcare, INC. | $22.71 | 2021 | |
| Biocryst US Sales Co., LLC | $18.77 | 2023 | Orladeyo |
| Kaleo, INC. | $16.91 | 2021 | |
| Hikma Pharmaceuticals USA | $16.32 | 2025 | Ryaltris |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.81 | 2021 | |
| Phadia US INC. | $12.12 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kellie Kozak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.